← All trials
NCT05437510
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 8, 2022
- Primary completion
- Apr 30, 2023
- Completion date
- Feb 28, 2024
- First posted
- Jun 29, 2022
- Last posted
- Nov 30, 2022
- Enrollment
- 28860
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sanofi-AventisLead sponsor
- AstraZenecaCollaborator
- SanofiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.